Wednesday, 14 October 2026European Markets

GREENVOLT Stock 9.4% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with GREENVOLT (GVOLT.LS) jumping 9.4% to €8.15 on Thursday while PSI jumped 0.69% to €6,388.46.

GREENVOLT's last close was €7.45, 29.85% below its 52-week high of €10.62.

About GREENVOLT

Greenvolt - Energias Renováveis, S.A. operates in the renewable energy sector in Portugal, the United Kingdom, and internationally. The company operates through Residual Biomass; Development of Wind and Solar Utility-Scale; and Distributed Generation segments. It is involved in operation and development of biomass plants, as well as development of wind and solar photovoltaic plants in the European markets. The company was formerly known as Bioelétrica da Foz, S.A. and changed its name to Greenvolt - Energias Renováveis, S.A. Greenvolt - Energias Renováveis, S.A. was incorporated in 2002 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, GREENVOLT has a trailing twelve months EPS of €0.03.

PE Ratio

GREENVOLT has a trailing twelve months price to earnings ratio of 271.67. Meaning, the purchaser of the share is investing €271.67 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.86%.

Yearly Top and Bottom Value

GREENVOLT's stock is valued at €8.15 at 21:35 EST, way below its 52-week high of €10.62 and way above its 52-week low of €5.84.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19.7%, now sitting on 270.64M for the twelve trailing months.

Volume

Today's last reported volume for GREENVOLT is 2331390 which is 360.95% above its average volume of 505770.

Moving Average

GREENVOLT's value is way above its 50-day moving average of €6.25 and way above its 200-day moving average of €7.00.

More news about GREENVOLT (GVOLT.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com